Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1753465816667659 http://scihub22266oqcxt.onion/10.1177/1753465816667659 C5933597!5933597!27612492     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Adv+Respir+Dis 2016 ; 10 (6): 534-48 Nephropedia Template TP {{tp|p=27612492|t=2016. The clinical profile of benralizumab in the management of severe eosinophilic asthma |pdf=|usr=}}{{27612492}} gab.com Text The clinical profile of benralizumab in the management of severe eosinophilic asthma JO: Ther Adv Respir Dis http://www.kidney.de/pget.php?&tw=1&pmid=27612492 #FOAvip Despite several therapeutic choices, 10?20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and interventional, that can result in improvement of severe asthma management, such as omalizumab, bronchial thermoplasty and other biological drugs, for example, mepolizumab, reslizumab and benralizumab. The availability of these new treatments and the increasing knowledge of the different asthmatic phenotypes and endotypes makes correct patient selection increasingly complex and important. In this article, we discuss the features of benralizumab compared with other anti-interleukin-5 biologics and omalizumab, the identification of appropriate patients, the safety profile and future developments. Twit Text FOAVip The clinical profile of benralizumab in the management of severe eosinophilic asthma ????Ther Adv Respir Dis http://www.kidney.de/pget.php?&tw=1&pmid=27612492 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27612492 #FOAvip English Wikipedia <ref>{{Cite pmid|27612492}}</ref> The clinical profile of benralizumab in the management of severe eosinophilic asthma #MMPMID27612492 Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L Ther Adv Respir Dis 2016[Dec]; 10 (6): 534-48 PMID27612492show ga Despite several therapeutic choices, 10?20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and interventional, that can result in improvement of severe asthma management, such as omalizumab, bronchial thermoplasty and other biological drugs, for example, mepolizumab, reslizumab and benralizumab. The availability of these new treatments and the increasing knowledge of the different asthmatic phenotypes and endotypes makes correct patient selection increasingly complex and important. In this article, we discuss the features of benralizumab compared with other anti-interleukin-5 biologics and omalizumab, the identification of appropriate patients, the safety profile and future developments. äThe clinical profile of benralizumab in the management of severe eosin(epmc).pdf DeepDyve Pubget Overpricing